PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

AASLD/IDSA 2025 Hepatitis B Guideline Shifts From Guidance to Recommendations

The first formal AASLD/IDSA HBV guideline (versus prior guidance) tightens antiviral treatment thresholds, adds tenofovir alafenamide for pregnancy, and newly addresses horizontal transmission and expanded liver cancer surveillance.
📅 Journal publication: Jul 2026 · Last updated: Sep 11, 2026
AASLD/IDSA 2025 Hepatitis B Practice GuidelineAmerican Association for the Study of Liver DiseasesInfectious Diseases Society of Americachronic hepatitis Bnucleos(t)ide analoguestenofovir alafenamidetenofovir disoproxil fumaratehepatocellular carcinoma surveillance Infectious Disease / Antimicrobials
Also in Gastroenterology / Hepatology

Background Information

New guidelines reshape hepatitis B virus management strategies.

Updated guidelines provide critical information on the management of hepatitis B virus (HBV), affecting treatment decisions and patient outcomes. The guidelines emphasize new evidence in antiviral therapy selection, monitoring strategies, and treatment initiation criteria. Clinicians must familiarize themselves with these guideline updates to optimize HBV management and improve patient care outcomes. Stay updated with the latest HBV management guidelines to ensure best practices in patient treatment.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Nguyen MH

Citation: Nguyen MH Highlights From the Recent AASLD/IDSA Guideline on Hepatitis B Virus Management. Gastroenterology & hepatology. 2026;22(7):381-384.

Article Links: PubMed · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Suggest a correction Request a topic
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.